Identifies themes and clusters of stock movements
Market TodayThemes and Stocks AnalysesThematic Stock SearchClick here for daily refresh schedule
GNFT - Genfit SA
0.21(4.38%)8:55:52 PM 11/24/2020
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.
Stock Chart
No summary

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Stock news

    GENFIT Announces Final Terms For Proposed Renegotiation of 2022 OCEANE Convertible Bonds

    * Company proposes to the 2022 OCEANEs holders a partial buyback at €16.40 euros per bond, subject to a €50 million euros buyback amount * Conversion ratio adjustment from 1: 1 to 1: 5.5; and * Additional amendments of 2022 OCEANEs terms Lille (France), Cambridge (Massachusetts, United States), November 23, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced the...

    GENFIT: New Data Presented at AASLD The Liver Meeting Digital Experience™

    * New data on the identification of at-risk NASH using NIS4™ technology alone or in combination with other non-invasive tests * New clinical data on NIS4™ technology as a prognostic biomarker to identify patients with higher likelihood of disease progression * Late breaker abstract on the detection of immune cells in liver tissue based on a combination of handcrafted and deep-learning approach * Other new NASH data including clinical data supporting the correlation of NASH activity scores wi...

    GENFIT: Third Quarter 2020 Financial Information and Launch of Renegotiation of Convertible Bond

    * Cash and cash equivalents of €199.3 million as of September 30, 2020 * Company proposes a partial buyback and an amendment of the existing terms of the 2022 OCEANEs                     Lille (France), Cambridge (Massachusetts, United States), November 16, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced its cash position as of September 30, 2020 and revenues ...

    Genfit SA to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / September 30, 2020 / Genfit SA (NASDAQ:GNFT) will be discussing their earnings results in their 2020 First Half Earnings call to be held on September 30, 2020 at 4:30 PM Eastern Time.

    GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

    * Innovative multi-biomarker blood test based on GENFIT’S NIS4™ technology is specifically designed to identify patients with at-risk non-alcoholic steatohepatitis (NASH) * LabCorp to commercialize the test for clinical care use in U.S. and Canada to help identify the approximately 10 million individuals at risk of progressing to late stage complications due to NASH among the tens of millions of people with metabolic risk factors and suspected disease * The test is expected to be available fro...

    The Daily Biotech Pulse: Novavax Advances Vaccine, Marinus Gets Nod For Late-Stage Study, 3 IPOs

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 24) * Beigene Ltd (NASDAQ: BGNE)) * Forte Biosciences Inc (NASDAQ: FBRX) * Pacific Biosciences of California Inc (NASDAQ: PACB)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 24) * ADiTx Therapeutics Inc (NASDAQ: ADTX) * AEterna Zentaris Inc. (NASDAQ: AEZS) * Akebia Therapeutics Inc (NASDAQ: AKBA) * Alector Inc (NASDAQ: ALEC) * AnPac Bio-Medi...